Impact of Trikafta on Lung Function in a Cystic Fibrosis Transplant Patient

Jakharia, Kunal; Doligalski, Christina T.; Lobo, Leonard J.; Coakley, Raymond D.

doi:10.1016/j.chest.2020.08.2019

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the sponsor noted that the only available data at the time of CADTH's review are case reports with small sample sizes. [106][107][108][109] Interpretation of Results…”

Section: The Inclusion and Exclusion Criteria For The Includedmentioning

confidence: 99%

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

CADTH¹

2022

cjht

View full text Add to dashboard Cite

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Elexacaftor-tezacaftor-ivacaftor and ivacaftor (Trikafta) 50 mg elexacaftor, 25 mg tezacaftor, and 37.5 mg ivacaftor (combination tablet) and 75 mg ivacaftor (tablet); oral 100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor (combination tablet) and 150 mg ivacaftor (tablet); oral. Indication: Treatment of cystic fibrosis in patients aged 6 years and older who have at least 1 F508del mutation in the CFTR gene.

show abstract

“…However, the sponsor noted that the only available data at the time of CADTH's review are case reports with small sample sizes. [106][107][108][109] Interpretation of Results…”

Section: The Inclusion and Exclusion Criteria For The Includedmentioning

confidence: 99%

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

CADTH¹

2022

cjht

View full text Add to dashboard Cite

show abstract

“…However, the sponsor notes that the only available data at the time of CADTH's review are case reports with small sample sizes. [82][83][84][85]…”

Section: Summary Of Available Evidencementioning

confidence: 99%

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Team¹

2021

cjht

View full text Add to dashboard Cite

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses ELX-TEZ-IVA (Trikafta) and ELX 100 mg, TEZ 50 mg, IVA 75 mg (combination tablet), and 150 mg IVA (tablet); oral. Indication: Treatment of cystic fibrosis in patients aged ≥ 12 years who have at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

show abstract

Multiple drugs

2020

Reactions Weekly

View full text Add to dashboard Cite

Impact of Trikafta on Lung Function in a Cystic Fibrosis Transplant Patient

Cited by 4 publications

References 0 publications

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Multiple drugs

Contact Info

Product

Resources

About